Research library
New reports, continuously.
Inherit checks GWAS Catalog, PGS Catalog, and ClinVar on a schedule. New report drafts go to people for review before they are published here. You can turn on email updates in Settings.
New report: Warfarin, one position · VKORC1
CPIC (a group of clinicians and scientists who write guidelines about genes and medicines) uses one position to name its two VKORC1 forms. This reads that position in VKORC1 and shows the letters your file has there. It says nothing about how warfarin works in you, and it is not a dose.
New report: Statins, the *5 position · SLCO1B1
CPIC (a group of clinicians and scientists who write guidelines about genes and medicines) writes a statin guideline that reads three genes. This reads one SLCO1B1 position in one of them: where a C marks the *5 form; *15, *40 and *47 carry it. It cannot say how statins work in you.
New report: Thiopurines, another position · TPMT
CPIC (a group of clinicians and scientists who write guidelines about genes and medicines) uses 45 positions to name TPMT forms. This reads the one where a T marks the *3B form; with a second position, not read here, it is part of *3A. It cannot say which pair of forms you carry, or how thiopurine medicines work in you.
New report: Thiopurines, the *2 position · TPMT
CPIC (a group of clinicians and scientists who write guidelines about genes and medicines) uses 45 positions to name TPMT forms. This reads the one where a G marks the *2 form. It cannot say which pair of TPMT forms you carry, or how thiopurine medicines work in you.
New report: Clopidogrel, one CYP2C19 position
CPIC (a group of clinicians and scientists who write guidelines about genes and medicines) uses 43 positions to name CYP2C19 forms. This reads one of them. A T here is part of the *17 form, and also of *44 and *45, so this is not a *17 call. It cannot say how clopidogrel works in you.
New report: Clopidogrel, the *2 position · CYP2C19
CPIC (a group of clinicians and scientists who write guidelines about genes and medicines) uses 43 positions to name CYP2C19 forms. This reads the one where an A marks the *2 form. It cannot say which pair of forms you carry, or how clopidogrel works in you.
New report: Warfarin and NSAIDs, the *3 position · CYP2C9
CPIC (a group of clinicians and scientists who write guidelines about genes and medicines) reads 88 CYP2C9 positions across both copies. This reads the one where a C marks the *3 form; *18 and *68 carry it. This cannot say which forms you carry, or how warfarin or NSAIDs work in you.
New report: Warfarin and NSAIDs, the *2 position · CYP2C9
CPIC (a group of clinicians and scientists who write guidelines about genes and medicines) reads 88 CYP2C9 positions across both copies. This reads the one where a T marks the *2 form; *35, *61 and *92 carry it. This cannot say which forms you carry, or how warfarin or NSAIDs work in you.
New report: Tacrolimus, the *3 position · CYP3A5
CPIC (a group of clinicians and scientists who write guidelines about genes and medicines) uses 7 positions to name CYP3A5 forms. This reads the one where a C marks the *3 form. It cannot say which pair of CYP3A5 forms you carry, or how tacrolimus works in you.
New report: Fluorouracil and capecitabine, the *2A position · DPYD
This is one of the positions guidelines list for DPYD. C on both copies here says nothing about the other positions, which this report does not read. CPIC (a group of clinicians and scientists who write guidelines about genes and medicines) uses 83 positions for DPYD. At this one, a T marks the *2A form. It cannot say how fluorouracil or capecitabine work in you.
New report: Thiopurines, one position · NUDT15
CPIC (a group of clinicians and scientists who write guidelines about genes and medicines) uses 20 positions to name NUDT15 forms. This reads one position where T occurs in CPIC’s *3 definition. This is not a *3 call: the other positions and your pair of forms are not read here. It cannot say how thiopurine medicines work in you.
Alcohol and caffeine study context updated
Added primary-study context to the alcohol and caffeine reports. The alcohol report includes a qualified finding about drinking and esophageal cancer. Caffeine now states the comparison actually tested instead of a universal speed label. Evidence labels are unchanged. Source trail: PR 59 and docs/metabolism-report-context.md.
Reviewed report wording published
Published previously merged wording and citation updates for 149 existing reports from main a9fbfc6b5aa703a52bf11864cf3025443b71ef03. No variant coordinates, alleles, genotype keys, evidence labels, report categories, score models or original publication dates changed. This is content parity, not new scientific validation.
Taste report association corrected
Corrected the rs1726866 PAV/AVI pattern association and removed the claim that two positions establish the full three-position pattern. Added source-linked study context to the taste, earwax and lactase reports. Evidence labels are unchanged; this is not a personal taste or clinical result. Reviewed source trail: PR 54 and docs/study-context-pilot.md.
How sure we are: what changed
- Evidence label re-mapped: Adiponectin levels · ADIPOQ moderate → emerging
- Evidence label re-mapped: Age at first period · LIN28B moderate → emerging
- Evidence label re-mapped: Age at natural menopause · MCM8 moderate → emerging
- Evidence label re-mapped: Alcohol consumption · KLB moderate → emerging
- Evidence label re-mapped: Alcohol dependence protection · ADH1B established → emerging
- Evidence label re-mapped: Alcohol dependence protection · ALDH2 established → emerging
- Evidence label re-mapped: Alcohol flush reaction · ALDH2 established → emerging
- Evidence label re-mapped: Alcohol metabolism speed · ADH1B established → emerging
- Evidence label re-mapped: Allergic sensitisation · IL13 moderate → emerging
- Evidence label re-mapped: ALS susceptibility · UNC13A moderate → emerging
- Evidence label re-mapped: Alzheimer's disease · APOE ε2/ε3/ε4 established → emerging
- Evidence label re-mapped: Alzheimer's disease · BIN1 moderate → emerging
- Evidence label re-mapped: Alzheimer's disease · CLU moderate → emerging
- Evidence label re-mapped: Alzheimer's disease · TREM2 R47H moderate → emerging
- Evidence label re-mapped: Androstenone smell perception · OR7D4 moderate → emerging
- Evidence label re-mapped: Ankylosing spondylitis · HLA-B27 tag established → emerging
- Evidence label re-mapped: Asparagus metabolite smell · olfactory receptor cluster (OR2M7) moderate → emerging
- Evidence label re-mapped: Atrial fibrillation · PITX2 region (4q25) moderate → emerging
- Evidence label re-mapped: Autoimmune thyroid disease · CTLA4 (CT60) moderate → emerging
- Evidence label re-mapped: Bilirubin processing · UGT1A1 established → emerging
- Evidence label re-mapped: Bipolar disorder association · ANK3 moderate → emerging
- Evidence label re-mapped: Bipolar disorder association · CACNA1C moderate → emerging
- Evidence label re-mapped: Bitter taste perception · TAS2R38 established → emerging
- Evidence label re-mapped: Bitter taste perception (PTC/PROP) · TAS2R38 established → emerging
- Evidence label re-mapped: Blond hair · KITLG enhancer moderate → emerging
- Evidence label re-mapped: Blood pressure · AGT M235T moderate → emerging
- Evidence label re-mapped: Blue vs. brown eye color · HERC2/OCA2 established → emerging
- Evidence label re-mapped: Body weight tendency · FTO established → emerging
- Evidence label re-mapped: Body weight tendency · MC4R region moderate → emerging
- Evidence label re-mapped: Breast cancer · 2q35 region moderate → emerging
- Evidence label re-mapped: Breast cancer · FGFR2 moderate → emerging
- Evidence label re-mapped: Caffeine metabolism · CYP1A2 moderate → emerging
- Evidence label re-mapped: Caffeine, anxiety & sleep · ADORA2A moderate → emerging
- Evidence label re-mapped: Celiac disease · HLA-DQ2.5 tag (HLA-DQA1) established → emerging
- Evidence label re-mapped: Celiac disease HLA background · HLA-DQA1 established → emerging
- Evidence label re-mapped: CFTR F508del carrier status (informational) · CFTR established → emerging
- Evidence label re-mapped: Cilantro soapy taste · OR6A2 region moderate → emerging
- Evidence label re-mapped: Cold sensitivity · TRPM8 moderate → emerging
- Evidence label re-mapped: Colorectal cancer · APC I1307K moderate → emerging
- Evidence label re-mapped: Colorectal cancer · SMAD7 (18q21) moderate → emerging
- Evidence label re-mapped: Coronary artery disease · 9p21 region established → emerging
- Evidence label re-mapped: Crohn's disease · NOD2 (R702W, G908R) established → emerging
- Evidence label re-mapped: Depression association · OLFM4 region moderate → emerging
- Evidence label re-mapped: Diet response and body weight · GIPR moderate → emerging
- Evidence label re-mapped: Dopamine D2 signaling · ANKK1/DRD2 Taq1A moderate → emerging
- Evidence label re-mapped: Earlobe attachment · EDAR moderate → emerging
- Evidence label re-mapped: Earwax type and body odor · ABCC11 established → emerging
- Evidence label re-mapped: Endometriosis · WNT4 region (1p36) moderate → emerging
- Evidence label re-mapped: Episodic memory · KIBRA moderate → emerging
- Evidence label re-mapped: Exceptional longevity · FOXO3 moderate → emerging
- Evidence label re-mapped: Executive function & stress · COMT moderate → emerging
- Evidence label re-mapped: Factor V Leiden · F5 established → emerging
- Evidence label re-mapped: Fasting glucose · MTNR1B moderate → emerging
- Evidence label re-mapped: Freckling and sun sensitivity · IRF4 moderate → emerging
- Evidence label re-mapped: Frontotemporal dementia · TMEM106B moderate → emerging
- Evidence label re-mapped: FSH receptor sensitivity · FSHR Asn680Ser moderate → emerging
- Evidence label re-mapped: Habitual caffeine intake · AHR moderate → emerging
- Evidence label re-mapped: Hair strand thickness · EDAR moderate → emerging
- Evidence label re-mapped: HDL cholesterol · CETP TaqIB moderate → emerging
- Evidence label re-mapped: Homocysteine · MTHFR C677T established → emerging
- Evidence label re-mapped: Inflammatory bowel disease · IL23R R381Q moderate → emerging
- Evidence label re-mapped: Insulin resistance · IRS1 region moderate → emerging
- Evidence label re-mapped: Iron overload (C282Y) · HFE established → emerging
- Evidence label re-mapped: Iron overload (H63D) · HFE established → emerging
- Evidence label re-mapped: Iron status · TMPRSS6 V736A moderate → emerging
- Evidence label re-mapped: Lactose tolerance · LCT/MCM6 established → emerging
- Evidence label re-mapped: LDL cholesterol · LDLR moderate → emerging
- Evidence label re-mapped: LDL cholesterol · SORT1 region (1p13) moderate → emerging
- Evidence label re-mapped: Lipoprotein(a) · LPA moderate → emerging
- Evidence label re-mapped: Liver fat tendency · PNPLA3 established → emerging
- Evidence label re-mapped: Longevity · APOE (e2/e3/e4) established → emerging
- Evidence label re-mapped: Lung cancer & glioma · TERT (5p15.33) moderate → emerging
- Evidence label re-mapped: Lung cancer & smoking intensity · CHRNA3 (15q25) moderate → emerging
- Evidence label re-mapped: Male-pattern hair loss · 20p11 locus moderate → emerging
- Evidence label re-mapped: Male-pattern hair loss · AR (X chromosome) moderate → emerging
- Evidence label re-mapped: Melanoma · MC1R R151C moderate → emerging
- Evidence label re-mapped: Memory & brain plasticity · BDNF moderate → emerging
- Evidence label re-mapped: Morning chronotype · RGS16 moderate → emerging
- Evidence label re-mapped: Motion sickness susceptibility moderate → emerging
- Evidence label re-mapped: Multiple sclerosis · HLA-DRB1*15:01 tag established → emerging
- Evidence label re-mapped: Muscle composition · ACTN3 R577X established → emerging
- Evidence label re-mapped: Nicotine dependence · CHRNA5 established → emerging
- Evidence label re-mapped: Norovirus resistance (secretor status) · FUT2 established → emerging
- Evidence label re-mapped: Omega-3/6 fatty acid conversion · FADS1 moderate → emerging
- Evidence label re-mapped: Opioid receptor variation · OPRM1 moderate → emerging
- Evidence label re-mapped: Parkinson's disease · GBA1 N370S established → emerging
- Evidence label re-mapped: Parkinson's disease · LRRK2 G2019S established → emerging
- Evidence label re-mapped: Parkinson's disease · SNCA moderate → emerging
- Evidence label re-mapped: Photic sneeze reflex · 2q22 region (near ZEB2) moderate → emerging
- Evidence label re-mapped: Photic sneeze reflex · rs10427255 moderate → emerging
- Evidence label re-mapped: Pregnancy and clotting · Factor V Leiden moderate → emerging
- Evidence label re-mapped: Prostate & colorectal cancer · 8q24 region moderate → emerging
- Evidence label re-mapped: Prostate cancer · MSMB moderate → emerging
- Evidence label re-mapped: Prothrombin G20210A · F2 established → emerging
- Evidence label re-mapped: Psoriasis · HLA-C*06:02 tag established → emerging
- Evidence label re-mapped: Red hair and fair skin · MC1R (R151C) established → emerging
- Evidence label re-mapped: Rheumatoid arthritis · PTPN22 R620W established → emerging
- Evidence label re-mapped: Skin pigmentation and tanning · SLC45A2 moderate → emerging
- Evidence label re-mapped: Smoking initiation · BDNF moderate → emerging
- Evidence label re-mapped: Sprint and power muscle fiber · ACTN3 established → emerging
- Evidence label re-mapped: Straight vs. curly hair · TCHH moderate → emerging
- Evidence label re-mapped: Stress & anxiety processing · COMT moderate → emerging
- Evidence label re-mapped: Stress hormone response · FKBP5 moderate → emerging
- Evidence label re-mapped: Sun sensitivity · MC1R R151C and R160W established → emerging
- Evidence label re-mapped: Systemic lupus erythematosus · STAT4 moderate → emerging
- Evidence label re-mapped: Tanning response and freckling · IRF4 moderate → emerging
- Evidence label re-mapped: Tauopathy risk · MAPT H1/H2 haplotype moderate → emerging
- Evidence label re-mapped: Telomere length · TERC region moderate → emerging
- Evidence label re-mapped: Telomere length · TERT moderate → emerging
- Evidence label re-mapped: Type 1 diabetes · HLA DR3-DQ2 / DR4-DQ8 tags established → emerging
- Evidence label re-mapped: Type 2 diabetes · KCNJ11 E23K moderate → emerging
- Evidence label re-mapped: Type 2 diabetes · PPARG Pro12Ala established → emerging
- Evidence label re-mapped: Type 2 diabetes · TCF7L2 established → emerging
- Evidence label re-mapped: UV sensitivity · SLC45A2 L374F moderate → emerging
- Evidence label re-mapped: Vitamin B12 levels · FUT2 moderate → emerging
- Evidence label re-mapped: Vitamin C levels · SLC23A1 moderate → emerging
- Evidence label re-mapped: Vitamin D from sunlight · GC moderate → emerging
- Evidence label re-mapped: Vitamin D levels · CYP2R1 moderate → emerging
- Evidence label re-mapped: Wet or dry earwax · ABCC11 established → emerging